pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$CRBUCaribou Biosciences, Inc.

$CRBU
Berkeley, CA, USupdated 3mo ago

Rachel Elizabeth Haurwitz is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 1: 2
2Phase 1
Phase 1
CB-011
Refractory Multiple Myeloma
DNA-directed RNA polymerase
Phase 1
vispacabtagene regedleucel
B-Cell Non-Hodgkin Lymphoma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • —Long-Term Follow-up Studyenrolling by invitationn=150
  • phase1CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myelomarecruitingn=50
  • phase1CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)withdrawn
  • phase1CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemiaterminatedn=12
  • phase1CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)recruitingn=72
🐶 Hiring Signal
1 open role at Caribou Biosciences, Inc. →

Where Caribou Biosciences, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 1

News

  • Biopharma layoffs rise YOY in October but sharply trend down for 2026
    October marked the first time this year there was an increase in both the number of biotech and pharma companies trimming their workforces and the number of affected employees when compared to 2025…
    biospace · 5d ago
  • In the hunt for reverse merger targets, Caribou could be prized game
    The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a likely candidate to receive reverse merger interest.
    biopharma_dive · 1mo ago
  • STAT+: Biotech companies are struggling to navigate Trump’s new tariffs
    Smaller biotech firms are trying to figure out how to win exemptions from Trump's import taxes.
    stat · 1mo ago
  • A mother-daughter quest to find fellow members of an ultra-rare genetic community
    “Don’t google,” the pediatric geneticist warned. It took me five years to disobey.
    stat · 1mo ago
  • STAT+: PhRMA sues over Trump policy mandating lower drug prices in Medicare
    The brand drug industry’s main trade group is suing the Trump administration over a pilot program tying Medicare drug prices to those in peer countries.
    stat · 1mo ago
  • Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate
    Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives…
    biopharma_dive · 1mo ago
  • STAT+: Forbion raises $2.6 billion, its largest fundraise to date
    Forbion, a prominent European venture capital firm, said it has raised $2.6 billion, its largest fundraise to date and one of the largest in the region in recent years.
    stat · 1mo ago
  • Cadrenal launches strategic review for late-stage cardiology pipeline
    Cadrenal Therapeutics, a heart-focused biotech that recently reached an agreement with the FDA on the design of a pivotal trial for its lead candidate, is now instead looking to offload its pipelin…
    fiercebiotech · 1mo ago
  • Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up
    Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including…
    biospace · 1mo ago
  • STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few
    Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.
    stat · 1mo ago
view all news mentions →
identifiers
ticker
$CRBU
SEC CIK
0001619856
country
US
source
sec_tickers
top tags
Oncology2DLBCL1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?